Workflow
Compared to Estimates, OrthoPediatrics (KIDS) Q4 Earnings: A Look at Key Metrics
KIDSOrthoPediatrics(KIDS) ZACKS·2025-03-05 00:00

Core Insights - OrthoPediatrics reported a revenue of 52.67millionforthequarterendedDecember2024,reflectinga4052.67 million for the quarter ended December 2024, reflecting a 40% increase year-over-year [1] - The earnings per share (EPS) was -0.29, a decline from -0.23inthesamequarterlastyear,withanEPSsurpriseof−31.820.23 in the same quarter last year, with an EPS surprise of -31.82% compared to the consensus estimate of -0.22 [1] - The revenue reported was slightly below the Zacks Consensus Estimate of 52.7million,resultinginasurpriseof−0.0652.7 million, resulting in a surprise of -0.06% [1] Revenue Performance - Trauma and deformity product sales reached 36.41 million, exceeding the average estimate of 35.25million,markingayear−over−yearincreaseof34.535.25 million, marking a year-over-year increase of 34.5% [4] - Sports medicine/other product sales were 0.63 million, falling short of the 1.12millionaverageestimate,representingayear−over−yeardeclineof29.21.12 million average estimate, representing a year-over-year decline of 29.2% [4] - Scoliosis product sales amounted to 15.63 million, surpassing the estimated $12.86 million, with a significant year-over-year increase of 61.8% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.7%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]